FDA clears Amgen’s Prolia for glucocorticoid osteoporosis
US regulators have approved a new indication for Amgen’s Prolia, allowing its use to treat glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture.
Read More
Tag: risedronate
Amgen’s Prolia shows promise in glucocorticoid osteoporosis
Top-line data from a late-stage trial of Amgen’s Prolia in osteoporosis patients receiving glucocorticoid therapy show that all primary and secondary targets being investigated were met.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
